The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 3 rounds in the feed, most often at Series D+ and in Biotech.
srone.comRounds from 2023-08-23 to 2026-07-07
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ ext. Published on thinner evidence, 3 sources | n/a | 2026-07-07 | [ LEAD ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ |
| $38M |
| 2025-05-22 |
| [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2023-08-23 | [ LEAD ] |